Back to results
US 2011/0212477 A1Published application
Lipoprotein-associated markers for cardiovascular disease
AssigneeUniversity of Washington
InventorsJay W. Heinecke, Tomas Vaisar
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeUniversity of Washington
InventorsJay W. Heinecke, Tomas Vaisar
Estimating the term…
The invention provides methods of screening a mammalian subject to determine if the subject is at risk to develop, or is suffering from, cardiovascular disease. The methods comprise detecting an amount of at least one biomarker in a biological sample, or HDL subfraction thereof, from the subject, and comparing the detected amount of the biomarker to a predetermined value, where a difference between the detected amount and the predetermined value is indicative of the presence or risk of cardiovascular disease in the subject. In some embodiments, the biomarker comprises at least one of ApoC-IV, Paraoxonase 1, C3, C4, ApoA-IV, ApoE, ApoL1, C4B1, Histone H2A, ApoC-II, ApoM, Vitronectin, Haptoglobin-related protein, and Clusterin, or combinations thereof.
A method of screening a mammalian subject to determine if the subject is at risk to develop, or is suffering from, cardiovascular disease, the method comprising detecting an amount of at least one biomarker in a biological sample, or HDL subfraction thereof, or a complex containing ApoA-I or ApoA-II of the subject, wherein the biomarker is selected from the group consisting of ApoC-IV, Paraoxonase 1, C3, C4, ApoL1, C4B1, Histone H2A, ApoC-II, ApoM, Vitronectin, Haptoglobin-related Protein, and Clusterin, combinations or portions and/or derivatives thereof, and then comparing the detected amount of the biomarker in the biological sample to a predetermined value, wherein a difference in the amount of the biomarker between the biological sample and the predetermined value is indicative of the presence or risk of cardiovascular disease in the subject.
Dependencies are inferred from the claim text.